Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2021

Feb 14, 2022

BUY
$132.01 - $190.29 $422,432 - $608,928
3,200 New
3,200 $143,000
Q2 2021

Aug 13, 2021

SELL
$144.0 - $179.73 $4.26 Million - $5.32 Million
-29,600 Closed
0 $0
Q1 2021

May 04, 2021

BUY
$158.92 - $221.61 $2.26 Million - $3.15 Million
14,200 Added 92.21%
29,600 $409,000
Q3 2020

Nov 03, 2020

BUY
$113.26 - $167.27 $962,710 - $1.42 Million
8,500 Added 123.19%
15,400 $66,000
Q2 2020

Aug 13, 2020

BUY
$72.01 - $120.39 $158,422 - $264,858
2,200 Added 46.81%
6,900 $10,000
Q1 2020

May 11, 2020

SELL
$69.78 - $116.21 $697,800 - $1.16 Million
-10,000 Reduced 68.03%
4,700 $195,000
Q4 2019

Feb 11, 2020

BUY
$70.76 - $128.86 $1.04 Million - $1.89 Million
14,700 New
14,700 $88,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Cowen And Company, LLC Portfolio

Follow Cowen And Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cowen And Company, LLC with notifications on news.